CertainT® for Cotton Traceability is an approach to authenticate goods within large and complex supply chains offered by Applied DNA Sciences. With this technique, materials such as cotton and leather, home textiles and apparel, pharmaceuticals and nutraceuticals, personal care, cannabis, and other products. CertainT® has ensured the authenticity of approximately 300 million pounds of North American Pima and Upland cotton and has been deployed to secure Egyptian and Australian cotton.
CertainT® begins by authenticating the fiber content in cotton to confirm its origin. The platform then employs a unique molecular identifier produced by the Company’s LinearDNA™ platform to mark cotton fibers in bulk. The cotton fiber is then tested for the identifier’s presence via the Company’s proprietary, portable readers. The cotton fiber travels throughout a global supply chain and is converted into yarn, fabric, and finished goods. The identifier’s detection confirms origin and authenticity; its absence can signal to blend with illicit cotton, including cotton potentially produced using forced labor.
The CertainT® logo signifies to consumers of cotton products that they can trust the products they are buying with said trust grounded in forensic, science-based authentication. Therefore, consumers can be confident in the knowledge that Brands and their supply chains have taken the necessary steps to assure that the cotton product itself is authentic and sustainably, and responsibly sourced from a known origin.
Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences. The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company’s deep expertise in DNA.
